Citations (88)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jian-hong Qi & Fang-xu Dong. (2021) The relevant targets of anti-oxidative stress: a review. Journal of Drug Targeting 29:7, pages 677-686.
Read now
Read now
Stanley Cohan. (2016) Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics: Targets and Therapy 10, pages 119-138.
Read now
Read now
Sybil Obuobi, Sanzhar Karatayev, Christina Li Lin Chai, Pui Lai Rachel Ee & Peter Mátyus. (2016) The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases. Journal of Enzyme Inhibition and Medicinal Chemistry 31:sup3, pages 194-204.
Read now
Read now
Nikolaos Grigoriadis, Michael Linnebank, Nektaria Alexandri, Sarah Muehl & Günther F. L. Hofbauer. (2016) Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opinion on Pharmacotherapy 17:15, pages 2085-2095.
Read now
Read now
Xiran Lin & Tian Huang. (2016) Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radical Research 50:6, pages 585-595.
Read now
Read now
Yara Dadalti Fragoso, Tarso Adoni, Andrea Anacleto, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Rinaldo Claudino, Alfredo Damasceno, Maria Lucia Brito Ferreira, Paulo Diniz da Gama, Marcus Vinicus Magno Goncalves, Anderson Kuntz Grzesiuk, Andre Palma da Cunha Matta & Monica Fiuza Koncke Parolin. (2014) How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?. Expert Review of Neurotherapeutics 14:11, pages 1251-1260.
Read now
Read now
Articles from other publishers (82)
Tetsuo Toyama, Tatiana V. Kudryashova, Asako Ichihara, Stefania Lenna, Agnieszka Looney, Yuanjun Shen, Lifeng Jiang, Leyla Teos, Theodore Avolio, Derek Lin, Ulas Kaplan, Grace Marden, Vrinda Dambal, Dmitry Goncharov, Horace Delisser, Robert Lafyatis, Francesca Seta, Elena A. Goncharova & Maria Trojanowska. (2023) GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension. Scientific Reports 13:1.
Crossref
Crossref
Rossella Basilotta, Marika Lanza, Alessia Filippone, Giovanna Casili, Deborah Mannino, Federica De Gaetano, Giulia Chisari, Lorenzo Colarossi, Gianmarco Motta, Michela Campolo, Salvatore Cuzzocrea, Irene Paterniti & Emanuela Esposito. (2023) Therapeutic Potential of Dimethyl Fumarate in Counteract Oral Squamous Cell Carcinoma Progression by Modulating Apoptosis, Oxidative Stress and Epithelial–Mesenchymal Transition. International Journal of Molecular Sciences 24:3, pages 2777.
Crossref
Crossref
Ralf Gold, Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Xavier Montalbán, Fu-Dong Shi, Mar Tintoré, Qun Xue, Chunsheng Yang & Hongyu Zhou. (2023) Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. Therapeutic Advances in Neurological Disorders 16.
Crossref
Crossref
Neda Sattarnezhad, Brian C. Healy, Moogeh Baharnoori, Camilo Diaz-Cruz, James Stankiewicz, Howard L. Weiner & Tanuja Chitnis. (2022) Comparison of dimethyl fumarate and interferon outcomes in an MS cohort. BMC Neurology 22:1.
Crossref
Crossref
Jacqueline A Nicholas, Mark Gudesblatt, Meghan Garabedian, Nicholas Belviso, Changyu Shen, Caroline Geremakis, Sai L Shankar, Jason P Mendoza & James B Lewin. (2022) Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Multiple Sclerosis and Related Disorders 63, pages 103921.
Crossref
Crossref
L. Magy. (2022) Traitements de fond de la sclérose en plaques. État des lieux et perspectives. Bulletin de l'Académie Nationale de Médecine 206:6, pages 741-751.
Crossref
Crossref
GHASEMIAN ELHAM, SADRAI SIMA, SHOKRI JAVAD & SAYADI SHAHRAM. (2021) ANALYTICAL METHOD VALIDATION, PHARMACOKINETICS AND BIOEQUIVALENCE STUDY OF DIMETHYL FUMARATE IN HEALTHY IRANIAN VOLUNTEERS. International Journal of Pharmacy and Pharmaceutical Sciences, pages 6-10.
Crossref
Crossref
Patricia K. Coyle, Anne Gocke, Megan Vignos & Scott D. Newsome. (2021) Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Advances in Therapy 38:7, pages 3550-3588.
Crossref
Crossref
Ayla Hoogendoorn, Thomas D. Avery, Jiahe Li, Christina Bursill, Andrew Abell & Peter M. Grace. (2021) Emerging Therapeutic Applications for Fumarates. Trends in Pharmacological Sciences 42:4, pages 239-254.
Crossref
Crossref
A. Nast, C. Smith, P.I. Spuls, G. Avila Valle, Z. Bata‐Csörgö, H. Boonen, E. De Jong, I. Garcia‐Doval, P. Gisondi, D. Kaur‐Knudsen, S. Mahil, T. Mälkönen, J.T. Maul, S. MburuU. Mrowietz, K. Reich, E. Remenyik, K.M. Rønholt, P.G. Sator, M. Schmitt‐Egenolf, M. Sikora, K. Strömer, O. Sundnes, D. TrigosG. Van Der Kraaij, N. Yawalkar & C. Dressler. (2021) EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology 35:2, pages 281-317.
Crossref
Crossref
E. Tsantes, E. Curti, D. Ferraro, A. Lugaresi, E. Baldi, S. Montepietra, P. Immovilli, A. M. Simone, L. Mancinelli, S. Strumia, F. Vitetta, M. Foschi, C. Ferri, C. Ferrarini, P. Sola & F. Granella. (2020) Dimethyl fumarate‐induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis. European Journal of Neurology 28:1, pages 269-277.
Crossref
Crossref
Shane M O’Carroll & Luke A J O’Neill. (2021) Targeting immunometabolism to treat COVID-19. Immunotherapy Advances 1:1.
Crossref
Crossref
Jingya Wang, Jin Yang, Mingnan Cao, Zhigang Zhao, Baoshan Cao & Siwang Yu. (2021) The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions. Current Research in Pharmacology and Drug Discovery 2, pages 100028.
Crossref
Crossref
Ravirajsinh N. Jadeja, Folami L. Powell & Pamela M. Martin. 2020. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications. Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications.
Andrew ChanJohn RoseEnrique AlvarezAmit Bar-OrHelmut ButzkuevenRobert J. FoxRalf GoldMark GudesblattJodi HaartsenTim SpelmanKaty WrightDiana FerraroPatrizia SolaSuzanne HodgkinsonTomas Kalincik, Jeannette Lechner-ScottChristopher McGuiganKaren SpachChongshu ChenSami FamFan Wu & Catherine Miller. (2020) Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurology Clinical Practice 10:6, pages 510-519.
Crossref
Crossref
Tomoya Takeda, Masanobu Tsubaki, Ryota Asano, Tatsuki Itoh, Motohiro Imano, Takao Satou & Shozo Nishida. (2020) Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-κB. Journal of Dermatological Science 99:3, pages 168-176.
Crossref
Crossref
Sarah A. Scuderi, Alessio Ardizzone, Irene Paterniti, Emanuela Esposito & Michela Campolo. (2020) Antioxidant and Anti-inflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. Antioxidants 9:7, pages 630.
Crossref
Crossref
Purva Sharma & Rajkumar Tulsawani. (2020) Ganoderma lucidum aqueous extract prevents hypobaric hypoxia induced memory deficit by modulating neurotransmission, neuroplasticity and maintaining redox homeostasis. Scientific Reports 10:1.
Crossref
Crossref
Joohee Lee, Kwangho Song, Paul Hiebert, Sabine Werner, Tae-Gyun Kim & Yeong Shik Kim. (2020) Tussilagonone Ameliorates Psoriatic Features in Keratinocytes and Imiquimod-Induced Psoriasis-Like Lesions in Mice via NRF2 Activation. Journal of Investigative Dermatology 140:6, pages 1223-1232.e4.
Crossref
Crossref
V. Pourcher. (2020) What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Revue Neurologique 176:4, pages 235-243.
Crossref
Crossref
Temitope Isaac Adelusi, Lei Du, Meng Hao, Xueyan Zhou, Qian Xuan, Chowdhury Apu, Ying Sun, Qian Lu & Xiaoxing Yin. (2020) Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy. Biomedicine & Pharmacotherapy 123, pages 109732.
Crossref
Crossref
Nadja Demitrowitz & Tjalf Ziemssen. (2020) Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. Kompass Autoimmun 2:4, pages 147-150.
Crossref
Crossref
Marina A. Lynch. (2020) Can the emerging field of immunometabolism provide insights into neuroinflammation?. Progress in Neurobiology 184, pages 101719.
Crossref
Crossref
Randa Sghaier, Thomas Nury, Valerio Leoni, Claudio Caccia, Jean-Paul Pais De Barros, Ameur Cherif, Anne Vejux, Thibault Moreau, Khalifa Limem, Mohammad Samadi, John J. Mackrill, Ahmed Slaheddine Masmoudi, Gérard Lizard & Amira Zarrouk. (2019) Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrial alterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. The Journal of Steroid Biochemistry and Molecular Biology 194, pages 105432.
Crossref
Crossref
I. M. Skoie, I. Dalen, R. Omdal & G. Jonsson. (2019) Malondialdehyde and advanced oxidation protein products are not increased in psoriasis: a controlled study. Archives of Dermatological Research 311:4, pages 299-308.
Crossref
Crossref
Gerardo G. Piroli, Allison M. Manuel, Tulsi Patel, Michael D. Walla, Liang Shi, Scott A. Lanci, Jingtian Wang, Ashley Galloway, Pavel I. Ortinski, Deanna S. Smith & Norma Frizzell. (2019) Identification of Novel Protein Targets of Dimethyl Fumarate Modification in Neurons and Astrocytes Reveals Actions Independent of Nrf2 Stabilization. Molecular & Cellular Proteomics 18:3, pages 504-519.
Crossref
Crossref
Arun Rajgopal, SamanthaJ Roloff, CharlieR Burns, DavidJ Fast & JeffreyD Scholten. (2019) The cytoprotective benefits of a turmeric, quercetin, and rosemary blend through activation of the oxidative stress pathway. Pharmacognosy Magazine 15:66, pages 449.
Crossref
Crossref
Kewal K. JainKewal K. Jain. 2019. The Handbook of Neuroprotection. The Handbook of Neuroprotection
643
766
.
Heng Jiang, Hui Wang & Mark De Ridder. (2018) Targeting antioxidant enzymes as a radiosensitizing strategy. Cancer Letters 438, pages 154-164.
Crossref
Crossref
Syed Zahid Ali Shah, Deming Zhao, Tariq Hussain, Naveed Sabir, Mazhar Hussain Mangi & Lifeng Yang. (2018) p62-Keap1-NRF2-ARE Pathway: A Contentious Player for Selective Targeting of Autophagy, Oxidative Stress and Mitochondrial Dysfunction in Prion Diseases. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Mark S. Freedman, Daniel Selchen, Alexandre Prat & Paul S. Giacomini. (2018) Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45:5, pages 489-503.
Crossref
Crossref
Manuela Cerina, Venu Narayanan, Anna Delank, Patrick Meuth, Stephanie Graebenitz, Kerstin Göbel, Alexander M. Herrmann, Stefanie Albrecht, Thiemo Daldrup, Thomas Seidenbecher, Ali Gorji, Tanja Kuhlmann, Heinz Wiendl, Christoph Kleinschnitz, Erwin J. Speckmann, Hans-Christian Pape, Sven G. Meuth & Thomas Budde. (2018) Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination. Brain Structure and Function 223:7, pages 3091-3106.
Crossref
Crossref
Tiffany J Braley, Amanda K Huber, Benjamin M Segal, Neeraj Kaplish, Rachel Saban, Jesse M Washnock-Schmid & Ronald D Chervin. (2018) A randomized, subject and rater-blinded, placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea. Sleep 41:8.
Crossref
Crossref
Stanley L. Cohan, Harold Moses, Jonathan Calkwood, Carlo Tornatore, Chris LaGanke, Kyle E. Smoot, Venkata Meka, Macaulay Okwuokenye, Christophe Hotermans, Jason P. Mendoza, Monica K. Mann & Leslie A. Meltzer. (2018) Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Multiple Sclerosis and Related Disorders 22, pages 27-34.
Crossref
Crossref
Lori Mayer, Mary Kay Fink, Carrie Sammarco & Lisa Laing. (2017) Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate. Drug Safety 41:4, pages 347-356.
Crossref
Crossref
Christian von HehnJonathan HowardShifang LiuVen MekaJoe PultzDevangi MehtaClaudia PradaSoma RayMichael R. EdwardsSarah I. Sheikh. (2018) Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurology Neuroimmunology & Neuroinflammation 5:1.
Crossref
Crossref
Hyunyoung Kim, Jeremy Thompson, Guangchen Ji, Vadivel Ganapathy & Volker Neugebauer. (2017) Monomethyl fumarate inhibits pain behaviors and amygdala activity in a rat arthritis model. Pain 158:12, pages 2376-2385.
Crossref
Crossref
Michela Campolo, Giovanna Casili, Marika Lanza, Alessia Filippone, Irene Paterniti, Salvatore Cuzzocrea & Emanuela Esposito. (2017) Multiple mechanisms of dimethyl fumarate in amyloid β-induced neurotoxicity in human neuronal cells. Journal of Cellular and Molecular Medicine.
Crossref
Crossref
Stjepana Kovac, Albena Dinkova Kostova, Alexander Herrmann, Nico Melzer, Sven Meuth & Ali Gorji. (2017) Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy—Mitochondria, Calcium Dynamics and Reactive Oxygen Species. International Journal of Molecular Sciences 18:9, pages 1935.
Crossref
Crossref
Cherie M. Southwood, Danielle M. Garshott, Chelsea R. Richardson, Navid Seraji-Bozorgzad, Andrew M. Fribley & Alexander Gow. (2017) Dimethyl fumarate ameliorates myoclonus stemming from protein misfolding in oligodendrocytes. Journal of Neurochemistry 142:1, pages 103-117.
Crossref
Crossref
Luisa QuintiSharadha Dayalan NaiduUlrike TrägerXiqun ChenKimberly Kegel-GleasonDavid LlèresColúm ConnollyVanita ChopraCho LowSébastien MoniotEllen SappAdelaide R. TousleyPetr VodickaMichael J. Van KaneganLinda S. KaltenbachLisa A. CrawfordMatthew FuszardMaureen HigginsJames R. C. MillerRuth E. FarmerVijay PotluriSusanta SamajdarLisa MeiselNingzhe ZhangAndrew SnyderRoss SteinSteven M. HerschLisa M. EllerbyEranthie Weerapana, Michael A. SchwarzschildClemens SteegbornBlair R. LeavittAlexei DegterevSarah J. TabriziDonald C. LoMarian DiFigliaLeslie M. ThompsonAlbena T. Dinkova-Kostova & Aleksey G. Kazantsev. (2017) KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences 114:23.
Crossref
Crossref
Andrew Chan, Gary Cutter, Robert J Fox, James Xiao, James B Lewin & Michael R Edwards. (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research 6:4, pages 313-323.
Crossref
Crossref
Amira Zarrouk, Thomas Nury, El-Mostafa Karym, Anne Vejux, Randa Sghaier, Catherine Gondcaille, Pierre Andreoletti, Doriane Trompier, Stéphane Savary, Mustapha Cherkaoui-Malki, Meryam Debbabi, Agnès Fromont, Jean-Marc Riedinger, Thibault Moreau & Gérard Lizard. (2017) Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158 N murine oligodendrocytes. The Journal of Steroid Biochemistry and Molecular Biology 169, pages 29-38.
Crossref
Crossref
Albena T Dinkova-Kostova & Aleksey G Kazantsev. (2017) Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases. Neurodegenerative Disease Management 7:2, pages 97-100.
Crossref
Crossref
Shoichi Nishimoto, Shin Koike, Naho Inoue, Toshihiro Suzuki & Yuki Ogasawara. (2017) Activation of Nrf2 attenuates carbonyl stress induced by methylglyoxal in human neuroblastoma cells: Increase in GSH levels is a critical event for the detoxification mechanism. Biochemical and Biophysical Research Communications 483:2, pages 874-879.
Crossref
Crossref
S. N. Levin & T. B. Kaplan. (2017) Infectious Complications of Novel Multiple Sclerosis Therapies. Current Infectious Disease Reports 19:2.
Crossref
Crossref
Joshua A. David, William J. Rifkin, Piul S. Rabbani & Daniel J. Ceradini. (2017) The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. Journal of Diabetes Research 2017, pages 1-15.
Crossref
Crossref
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
439
473
.
Thomas Berger, Irina Elovaara, Sten Fredrikson, Chris McGuigan, Lucia Moiola, Kjell-Morten Myhr, Celia Oreja-Guevara, Igor Stoliarov & Uwe K. Zettl. (2016) Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs 31:1, pages 33-50.
Crossref
Crossref
Radek Ampapa & Stanislav Kopecký. (2016) Safety aspects of treating relapsing-remitting multiple sclerosis. Neurologie pro praxi 17:5, pages 300-304.
Crossref
Crossref
Lucia Romano Bernardini, Chiara Zecca, Valentina Torri Clerici, Claudio Gobbi, Renato Mantegazza & Silvia Rossi. (2016) Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis. Journal of the Neurological Sciences 369, pages 139-140.
Crossref
Crossref
Zhen-Gang Ma, Rui Ma, Xiao-Lin Xiao, Yong-Hui Zhang, Xin-Zi Zhang, Nan Hu, Jin-Lai Gao, Yu-Feng Zheng, De-Li Dong & Zhi-Jie Sun. (2016) Azo polymeric micelles designed for colon-targeted dimethyl fumarate delivery for colon cancer therapy. Acta Biomaterialia 44, pages 323-331.
Crossref
Crossref
Tony S. Gibson. 2016. Bioactive Carboxylic Compound Classes: Pharmaceuticals and Agrochemicals. Bioactive Carboxylic Compound Classes: Pharmaceuticals and Agrochemicals
209
220
.
Aaron E. Miller. (2016) Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology 22:3, pages 851-863.
Crossref
Crossref
L. Klotz, A. Berthele, W. Brück, A. Chan, P. Flachenecker, R. Gold, A. Haghikia, K. Hellwig, B. Hemmer, R. Hohlfeld, T. Korn, T. Kümpfel, M. Lang, V. Limmroth, R. A. Linker, U. Meier, S. G. Meuth, F. Paul, A. Salmen, M. Stangel, B. Tackenberg, H. Tumani, C. Warnke, M. S. Weber, T. Ziemssen, F. Zipp & H. Wiendl. (2016) Monitoring von Blutparametern unter verlaufsmodifizierender MS-TherapieMonitoring of blood parameters under course-modified MS therapy. Der Nervenarzt 87:6, pages 645-659.
Crossref
Crossref
Michael J. Van Kanegan, Denise E. Dunn, Linda S. Kaltenbach, Bijal Shah, Dong Ning He, Daniel D. McCoy, Peiying Yang, Jiangnan Peng, Li Shen, Lin Du, Robert H. Cichewicz, Robert A. Newman & Donald C. Lo. (2016) Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke. Scientific Reports 6:1.
Crossref
Crossref
Sofia Anastasiadou & Bernd Knöll. (2016) The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration. Experimental Neurology 279, pages 243-260.
Crossref
Crossref
Pierre Branger, Jean-Jacques Parienti, Maria Pia Sormani & Gilles Defer. (2016) The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis. PLOS ONE 11:3, pages e0149685.
Crossref
Crossref
Zbyšek Pavelek, Jan Krejsek & Martin Vališ. (2016) Role of T and B cells in pathogenesis of multiple sclerosis. Neurologie pro praxi 17:2, pages 100-103.
Crossref
Crossref
Giles E. Hardingham & Kim Q. Do. (2016) Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nature Reviews Neuroscience 17:2, pages 125-134.
Crossref
Crossref
Aniket Nikam, Anthony Ollivier, Michael Rivard, Jayne Louise Wilson, Kevin Mebarki, Thierry Martens, Jean-Luc Dubois-Randé, Roberto Motterlini & Roberta Foresti. (2016) Diverse Nrf2 Activators Coordinated to Cobalt Carbonyls Induce Heme Oxygenase-1 and Release Carbon Monoxide in Vitro and in Vivo. Journal of Medicinal Chemistry 59:2, pages 756-762.
Crossref
Crossref
Rui Li, Ayman Rezk, Luke M. Healy, Gillian Muirhead, Alexandre Prat, Jennifer L. Gommerman & Amit Bar-Or. (2016) Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. Frontiers in Immunology 6.
Crossref
Crossref
Przemysław Puz & Anetta Lasek-Bal. (2016) Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients. Medical Science Monitor 22, pages 4277-4282.
Crossref
Crossref
Valerio Chiurchiù, Antonio Orlacchio & Mauro Maccarrone. (2016) Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. Oxidative Medicine and Cellular Longevity 2016, pages 1-11.
Crossref
Crossref
Pierre Duquette, Paul S. Giacomini, Virender Bhan, Marika Hohol & Robyn Schecter. (2015) Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 43:1, pages 33-43.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
462
463
.
Gavin Giovannoni, Ralf Gold, Robert J. Fox, Ludwig Kappos, Mariko Kita, Minhua Yang, Sujata P. Sarda, Ray Zhang, Vissia Viglietta & Eva Havrdova. (2015) Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics 37:11, pages 2543-2551.
Crossref
Crossref
Roberta Foresti, Claudio Bucolo, Chiara Maria Bianca Platania, Filippo Drago, Jean-Luc Dubois-Randé & Roberto Motterlini. (2015) Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacological Research 99, pages 296-307.
Crossref
Crossref
Neeta Garg & Thomas W. Smith. (2015) An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain and Behavior 5:9.
Crossref
Crossref
Brandon L. Probst, Lyndsey McCauley, Isaac Trevino, W. Christian Wigley & Deborah A. Ferguson. (2015) Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. PLOS ONE 10:8, pages e0135257.
Crossref
Crossref
Xin Xie, Yu Zhao, Chun-Yan Ma, Xiao-Ming Xu, Yan-Qiu Zhang, Chen-Guang Wang, Jing Jin, Xin Shen, Jin-Lai Gao, Na Li, Zhi-Jie Sun & De-Li Dong. (2015) Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway. British Journal of Pharmacology 172:15, pages 3929-3943.
Crossref
Crossref
Ivraj Singh SandhuNicholas James MaksimEva Alice AmouzouganBryce Wilson GallionAnthony L.J. RavieleAikseng Ooi. (2015) Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochemical Society Transactions 43:4, pages 650-656.
Crossref
Crossref
Geoffrey O. Gillard, Brian Collette, John Anderson, Jianhua Chao, Robert H. Scannevin, David J. Huss & Jason D. Fontenot. (2015) DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner. Journal of Neuroimmunology 283, pages 74-85.
Crossref
Crossref
Laure Michel, Catherine Larochelle & Alexandre Prat. (2015) Update on treatments in multiple sclerosis. La Presse Médicale 44:4, pages e137-e151.
Crossref
Crossref
Hailin ZhengMati FridkinMoussa Youdim. (2015) New Approaches to Treating Alzheimer's Disease. Perspectives in Medicinal Chemistry 7, pages PMC.S13210.
Crossref
Crossref
Roberto Bomprezzi. (2015) Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Therapeutic Advances in Neurological Disorders 8:1, pages 20-30.
Crossref
Crossref
Danielle R. Bruns, Joshua C. Drake, Laurie M. Biela, Frederick F. Peelor, Benjamin F. Miller & Karyn L. Hamilton. (2015) Nrf2 Signaling and the Slowed Aging Phenotype: Evidence from Long-Lived Models. Oxidative Medicine and Cellular Longevity 2015, pages 1-15.
Crossref
Crossref
Christine M. Karbowski, Melissa M. Martin & Paul Nioi. 2015. Studies on Experimental Toxicology and Pharmacology. Studies on Experimental Toxicology and Pharmacology
467
480
.
Naphtali Savion, Nira Izigov, Milana Morein, Sarah Pri-Chen & Shlomo Kotev-Emeth. (2014) S-Allylmercapto-N-acetylcysteine (ASSNAC) protects cultured nerve cells from oxidative stress and attenuates experimental autoimmune encephalomyelitis. Neuroscience Letters 583, pages 108-113.
Crossref
Crossref
Eun Seong Hwang. (2014) Senescence suppressors: their practical importance in replicative lifespan extension in stem cells. Cellular and Molecular Life Sciences 71:21, pages 4207-4219.
Crossref
Crossref
Andreia N Carvalho, Jamie L Lim, Philip G Nijland, Maarten E Witte & Jack Van Horssen. (2014) Glutathione in multiple sclerosis: More than just an antioxidant?. Multiple Sclerosis Journal 20:11, pages 1425-1431.
Crossref
Crossref
Martin Marziniak & Sven Meuth. (2014) Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. Advances in Therapy 31:9, pages 915-931.
Crossref
Crossref